natgillin/translations-raw huggingface dataset:
the step of subjecting the semi-finished product (2') covered by the constraint film (1) to a thermal curing cycle so as to cause the polymerization of the thermosetting resin (4) with the subsequent irreversible solidification thereof. 
korak u kojem se poluproizvod (2'), koji je prekriven filmom za učvršćivanje (1), izlaže ciklusu stvrdnjavanja pod toplinom kako bi doveo do polimerizacije termostabilne smole (4) i potom njezinog nepovratnog skrućivanja.
A production method of composite material artefacts according to claim 18, characterised by also comprising, once the constraint film (1) is removed from the semi-finished product (2'), the step of applying on the outer coating film (5) of the resulting artefact (2), a layer of transparent paint, or a layer of thermosetting transparent resin, or a transparent plastic polymer film. 
Postupak proizvodnje predmeta od kompozitnih materijala prema patentnom zahtjevu 18, naznačen time, da nakon uklanjanja filma za učvršćivanje (1) iz poluproizvoda (2') obuhvaća i korak nanošenja sloja prozirne boje, sloja termostabilne prozirne smole ili prozirnog plastičnog polimernog filma na vanjski tankoslojni premaz (5) dobivenog proizvoda (2).
Pertuzumab for use according to claim 1 wherein the cancer is advanced, refractory or recurrent ovarian cancer. 
Pertuzumab za uporabu prema zahtjevu 1, naznačen time, da je taj rak napredujući, otporan ili ponavljajući rak jajnika.
Pertuzumab for use according to claim 1 or claim 2 wherein the pertuzumab is administered in the method as a single anti-tumor agent. 
Pertuzumab za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time, da se pertuzumab daje u postupku kao pojedinačno protutumorsko sredstvo.
Pertuzumab for use according to claim 4 wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, HER antibody, antibody directed against a tumor associated antigen, anti- hormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, liposomal doxorubicin, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD- 7200, a medicament that treats nausea, a medicament that prevents or treats skin rash or standard acne therapy, a medicament that treats or prevents diarrhea, a body temperature-reducing medicament, and a hematopoietic growth factor. 
Pertuzumab za uporabu prema zahtjevu 4, naznačen time, da je drugo terapeutsko sredstvo odabrano iz skupine koju čine: kemoterapeutsko sredstvo, HER-protutijelo, protutijelo usmjereno protiv antigena povezanog s tumorom, antihormonalni spoj, kardioprotektant, citokin, EGFR-ciljani lijek, anti-angiogensko sredstvo, inhibitor tirozin kinaze, COX-inhibitor, nesteroidni protuupalni lijek, inhibitor transferaze farnesila, protutijelo koje veže onkofetalni protein CA 125, HER2-cjepivo, HER-ciljana terapija, Raf-inhibitor ili ras-inhibitor, liposomalni doksorubicin, topotekan, taksan, dvostruki inhibitor tirozin kinaze, TLK286, EMD-7200, lijek koji sprečava mučninu, lijek koji sprečava ili liječi kožni osip ili standardna terapija za akne, lijek koji liječi ili sprečava proljev, lijek koji smanjuje tjelesnu temperaturu i hematopoietični faktor rasta.
Pertuzumab for use according to claim 5 wherein the second therapeutic agent is a chemotherapeutic agent. 
Pertuzumab za uporabu prema zahtjevu 5, naznačen time, da drugo terapeutsko sredstvo je kemoterapeutsko sredstvo.
Pertuzumab for use according to claim 16 wherein the chemotherapeutic agent is an antimetabolite chemotherapeutic agent. 
Pertuzumab za uporabu prema zahtjevu 16, naznačen time, da kemoterapeutsko sredstvo je antimetaboličko kemoterapeutsko sredstvo.
Pertuzumab for use according to claim 17 wherein the antimetabolite chemotherapeutic agent is gemcitabine. 
Pertuzumab za uporabu prema zahtjevu 17, naznačen time, da antimetaboličko kemoterapeutsko sredstvo je gemcitabin.
Pertuzumab for use according to any one of the preceding claims wherein in the method administration of pertuzumab extends TTP or survival at least 20% more than TTP or survival achieved by administering an approved anti-tumor agent to the cancer patient. 
Pertuzumab za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se u postupku primjene pertuzumaba produljuje TTP ili preživljavanje barem 20% više nego što je TTP ili preživljavanje postignuto primjenom jednog odobrenog antitumorskog sredstva na pacijentu koji boluje od raka.
Pertuzumab for use according to claim 13 wherein the patient has advanced, refractory or recurrent cancer. 
Pertuzumab za uporabu prema zahtjevu 13, naznačen time, da pacijent boluje od napredujućeg, otpornog ili ponavljajućeg raka.
Pertuzumab for use according to claim 13 or claim 14wherein in the method administration of pertuzumab to the patient extends TTP or survival at least 20% more than TTP or survival achieved by administering topotecan or liposomal doxorubicin to the patient. 
Pertuzumab za uporabu prema zahtjevu 13 ili zahtjevu 14, naznačen time, da se postupkom davanja pertuzumaba pacijentu produljuje TTP ili preživljavanje barem 20% više nego što je TTP ili preživljavanje postignuto primjenom topotekana ili liposomalnog doksorubicina kod pacijenta.
iii) hydrolyzing a compound of formula (VII) to obtain a compound of formula (IA). 
iii) hidroliza spoja formule (VII), pri čemu nastaje spoj formule (IA).
The process as claimed in claim 1 or 2 further comprising the steps of isolating and crystallising the compound of formula (IA). 
Postupak kako je prijavljen u patentnom zahtjevu 1 ili 2, naznačen time da dalje obuhvaća korake izolacije i kristalizacije spoja formule (IA).
The process as claimed in claim 4 wherein the palladium catalyst is a 1:2 w/w mixture of Pd(OCOCH3)2 and PPh3. 
Postupak kako je prijavljen u patentnom zahtjevu 4, naznačen time da paladijev katalizator jest 1: 2 w/w smjesa Pd(OCOCH3)2 i PPh3.
ii) transforming the compound of formula (III) into the corresponding nitrile derivative of formula (IV). 
ii) pretvorba spoja formule (III) u odgovarajući nitrilni derivat formule (IV).
The process as claimed in claim 6, wherein the bromination step is conducted with N-bromosuccinimide in the presence of a catalytic amount of benzoyl peroxide using acetonitrile as a solvent. 
Postupak kako je prijavljen u patentnom zahtjevu 6, naznačen time da se korak bromiranja provodi s N-bromsukcinimidom u prisutnosti katalitičke količine benzoil-peroksida u acetonitrilu kao otpalu.
The process as claimed in claim 7 wherein the compound of formula (1A) is 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid. 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da spoj formule (1A) jest 1-(3’,4’-diklor-2-fluor[1,1’-bifenil]-4-il)-ciklopropankarboksilna kiselina.
The fishhook according to claim 1, characterized in that a smaller number grooves (3) are formed in a small-sized hook. 
Udica prema zahtjevu 1, naznačena time da se manji broj udubljenja (3) formira kod udice manje veličine.
A process for removing or reducing an impurity from solid 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-HBr or from a solution of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-HBr, the process comprising the steps of 
Postupak uklanjanja ili reduciranja onečišćenja iz krutog 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr ili iz otopine 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr, postupak obuhvaća korake
The compound according to claim 17 having an XRPD as depicted in figure 2. 
Spoj prema zahtjevu 17 koji ima XRPD kako je prikazan na Slici 2.
The compound of claim 1 wherein R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, or tetrahydrofuranyl; and R2 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 (C1-C6)alkil, (C3-C7)cikloalkil ili tetrahidrofuranil; a R2 je vodik ili metil; ili njegova farmaceutski prihvatljiva sol.
A high-energy feed pellet according to one or more of claims 1-4, characterised in that the swelling capacity of the feed pellet is at least 40 ml after 30 minutes, preferably at least 30 ml after 20 minutes, in particular at least 20 ml after 10 minutes, based on 50 g of feed pellets. 
Visoko-energetske hranjive pelete prema jednom ili više od zahtjeva 1-4, naznačeno time što je kapacitet bubrenja u hranjivim peletama najmanje 30 ml nakon 20 minuta, poželjno najmanje 20 ml nakon 10 minuta, na temelju 50 g hranjivih peleta.
A high-energy feed pellet according to one or more of claims 1-5, characterised in that the sedimentation value of the feed pellet after 30 minutes is at most 60 ml, based on 50 g of feed pellets. 
Visoko-energetske hranjive pelete prema jednom ili više od zahtjeva 1-5, naznačeno time što je vrijednost sedimentacije u hranjivim peletama nakon 30 minuta najviše 60 ml, na temelju 50 g hranjivih peleta.
A high-energy feed pellet according to claim 6, characterised in that the sedimentation value of the feed pellet after 30 minutes is at most 25 ml, based on 50 g of feed pellets. 
Visoko-energetske hranjive pelete prema zahtjevu 6, naznačeno time što je vrijednost sedimentacije u hranjivim peletama nakon 30 minuta najviše 25 ml, na temelju 50 g hranjivih peleta.
A high-energy feed pellet according to one or more of claims 1-7, characterised in that the feed pellet comprises a fat selected from the group consisting of animal fats, vegetable fats, vegetable oils and vegetable fatty acids. 
Visoko-energetske hranjive pelete prema jednom ili više od zahtjeva 1-7, naznačeno time što hranjiva peleta sadrži masnoću izabranu iz grupe koja obuhvaća životinjske masti, biljne masti, biljna ulja i biljne masne kiseline.
A high-energy feed pellet according to one or more of claims 1-8, characterised in that the energy value (EV) is at least 1.25, preferably at least 1.55, more preferably at least 1.70, in particular at least 1.85 and above all 2.00 per kilogram of feed pellets, with 1 EV corresponding to 2100 kcal. 
Visoko-energetske hranjive pelete prema jednom ili više od zahtjeva 1-8, naznačeno time što je energetska vrijednost (EV) najmanje 1.25, poželjno najmanje 1.55, poželjnije najmanje 1.70, posebno najmanje 1.85 i najpoželjnije 2.00 po kilogramu hranjivih peleta, pri čemu 1 EV odgovara 2100 kcal.
A method for the preparation of a high-energy feed pellet based on natural materials in which the starting materials are mixed and processed to obtain a feed pellet, characterised in that the method comprises the following steps: 
Postupak pripreme visoko-energetskih hranjivih peleta prema bilo kojem od prethodnih zahtjeva, te visoko-energetske hranjive pelete su na bazi prirodnih materijala, gdje se početni materijali miješaju i obrađuju da se dobiju hranjive pelete, naznačeno time što postupak obuhvaća sljedeće korake:
providing a starch-containing composition having an average particle size of 200-650 µm; 
nabava smjese koja sadrži škrob i ima prosječnu veličinu čestica od 200-650 mm;
extruding the product obtained in step b) to obtain a feed pellet; 
ekstruzija proizvoda dobivenog u koraku b) radi dobivanja hranjive pelete;
introducing a fat-containing composition into the feed pellet obtained in step c) in a vacuum; and 
uvođenje smjese koja sadrži masnoću u hranjive pelete dobivene u koraku c) u vakuumu; i
A method according to one or more of claims 10-13, characterised in that after step c) an extra step, f), is carried out, comprising: 
Postupak prema jednom ili više od zahtjeva 10-13, naznačeno time što se nakon koraka c) provodi dodatni korak f) koji obuhvaća:
A method according to one or more of claims 10-15, characterised in that the fat content of the fat-containing composition is at least 75 wt.%, prefer-ably at least 85 wt.%, in particular at least 95 wt.% and above all at least 99 wt.%. 
Postupak prema jednom ili više od zahtjeva 10-15, naznačeno time što je sadržaj masti u smjesi koji sadrži masti najmanje 75 tež.%, poželjno najmanje 85 tež.%, posebno najmanje 95 tež.% i najpoželjnije da je najmanje 99 tež.%.
A method according to one or more of claims 10-16, characterised in that the fat-containing composition contributes at least 50 %, preferably at least 70 %, in particular at least 80 % and above all at least 90 % to the total fat content of the feed pellet. 
Postupak prema jednom ili više od zahtjeva 10-16, naznačeno time što smjesa koja sadrži masti predstavlja najmanje 50%, poželjno najmanje 70%, posebno najmanje 80% i najpoželjnije najmanje 90% ukupnog sadržaja masti u hranjivim peletama.
Use of the high-energy feed pellet according to one or more of claims 1-9 or obtained using a method according to one or more of claims 10-17 as feed for an animal selected from the group consisting of pig, cattle goat, sheep, horse, dog, and fish. 
Uporaba visoko-energetskih hranjivih peleta prema jednom ili više od zahtjeva 1-9 ili dobivenih prema postupku prema jednom ili više od zahtjeva 10-17 kao hrane za životinju izabranu iz grupe koja obuhvaća svinje, govedo, koze, ovce, konje, pse i ribe.
The system according to claim 1 or 2, characterised in that said first stage (2) comprises means (22, 23) for separating by gravity said heavy fraction from said mixture and for discharging (24) said separate heavy fraction. 
Sustav prema zahtjevu 1 ili 2, naznačen time što prva faza (2) obuhvaća sredstva (22, 23) za gravitacijsko razdvajanje teške frakcije od smjese i za izbacivanje (24) tako razdvojene teške frakcije.
The system according to any of claims 1 to 3, characterised in that said first separation means (4) for separating the light fraction comprise at least one of a comb conveyor (16) and a suction system (5). 
Sustav prema bilo kojem od zahtjeva 1 do 3, naznačen time što prva separacijska sredstva (4) za razdvajanje lagane frakcije obuhvaćaju barem jedno između pokretne trake u izvedbi češlja (16) i usisnog sustava (5).
The system according to one of claims 1 to 5, characterised by comprising means (32) for recirculating a portion of said mixture from said homogenising chamber (30) to said second stage (3). 
Sustav prema bilo kojem od zahtjeva 1 do 5, naznačen time što obuhvaća sredstva (32) za preusmjeravanje protoka dijela smjese iz homogenizirajuće komore (30) u drugu fazu (3).
The system according to one of claims 5 or 6, characterised by comprising a control system (100) configured to adjust a water flow rate entering the system (1) as a function of an energy absorption signal by said means (6, 32) for recirculating said mixture. 
Sustav prema jednom od zahtjeva 5 ili 6, naznačen time što obuhvaća kontrolni sustav (100) podešen da prilagođava brzinu protoka vode koja ulazi u sustav (1) kao funkciju signala apsorpcije energije iz sredstava (6, 32) za preusmjeravanje protoka smjese.
a catheter shaft (30) for connecting the catheter tip (10) to a handle (70), the catheter shaft (30) comprising: 
kateterska spojka (30) za spajanje vrha katetera (10) na dršku (70), kateterska spojka (30) obuhvaća:
first force transmitting means (31) with a distal end section connected to the first sleeve-shaped member (11) and a proximal end section connectable to first operating means (71) of the handle (70); and 
prva sredstva za prijenos sile (31) s distalnim krajem spojenim na prvi cjevasti član (11) i proksimalnim krajem koji se može spojiti s prvim operativnim sredstvima (71) drške (70); i
The insertion system (100) according to claim 1, wherein the guiding tube (52) is made from a material allowing the guiding tube (52) to be capable of traversing a tortuous pathway in the body of the patient without kinking. 
Sustav za umetanje (100) prema zahtjevu 1, gdje je provodna cjevčica (52) napravljena od materijala koji omogućuje da provodna cjevčica (52) može prolaziti kroz zavojite putove u tijelu bolesnika uvrtanja.
wherein the first catheter tube (32) is disposed concentrically and coaxially with the second catheter tube (42); and wherein the first catheter tube (32) preferably has a length which is the same as, or substantially similar to the length of the second catheter tube (42). 
gdje se prva kateterska cjevčica (32) nalazi koncentrično i koaksijalno prema drugoj kateterskoj cjevčici (42); i gdje prva kateterska cjevčica (32) ima dužinu koja je jednaka, ili u biti slična, dužini druge kateterske cjevčice (42).
The insertion system (100) according to claim 4, wherein the second lumen defined by the second catheter tube (42) has a diameter sufficient to accommodate a guide wire (180). 
Sustav za umetanje (100) prema zahtjevu 4, gdje drugi lumen definiran drugom kateterskom cjevčicom (42) ima promjer dovoljan za smještaj provodne žice (180).
The insertion system (100) according to claim 4 or 5, wherein the first catheter tube (32) terminates at its distal end in a flared section, said flared section defining a transition to the first sleeve-shaped member (11) of the seat portion, and wherein the flared section is preferably formed integrally with the distal end section of the first catheter tube (32). 
Sustav za umetanje (100) prema zahtjevu 4 ili 5, gdje prva kateterska cjevčica (32) završava na svom distalnom kraju proširenjem, to proširenje definira prijelaz prema prvom cjevastom članu (11) dijela za smještaj, i gdje je proširenje poželjno formirano integralno s distalnim krajem prve kateterske cjevčice (32).
The insertion system (100) according to one of the claims 4 to 6, wherein the first catheter tube (32) is made from a bendable but inflexible material and wherein at least the proximal end section of the first catheter tube (32) is preferably made of a braided wire construction preferably . 
Sustav za umetanje (100) prema jednom od zahtjeva 4 do 6, gdje je prva kateterska cjevčica (32) napravljena od savitljivog, ali čvrstog materijala i gdje je barem proksimalni kraj prve kateterske cjevčice (32) poželjno napravljen od konstrukcije ispletene žice.
A medical device for treatment of a heart valve defect, in particular a heart valve failure or a heart valve stenosis in a patient, wherein the medical device has an insertion system (100) in accordance with one of the claims 12 to 14 and an expandable heart valve stent (150) accommodated in the catheter tip (10) of the insertion system (100). 
Medicinski proizvod za liječenje poremećaja srčanog zaliska, posebno zatajenja srčanog zaliska ili stenoze srčanog zaliska u bolesnika, pri čemu medicinski proizvod ima sustav za umetanje (100) prema jednom od zahtjeva 1 do 13 i šireći stent za srčani zalistak (150) smješten u vrhu katetera (10) sustava za umetanje (100).
Machine according to Claim 1, characterized in that each of the canisters (1) is provided on its lower end with a corresponding baseplate (2) made in any way such that the canister can be gripped and manipulated by the various components of the machine. 
Uređaj temeljem zahtjeva 1, naznačen time što svaki od spremnika (1) na svojem donjem kraju ima odgovarajuću baznu ploču (2) izrađenu na bilo koji način tako da spremnik može biti držan i da njime mogu rukovati različite komponente uređaja.
an imidazoquinolin(amine) compound selected from following formula (I): wherein 
spoj imidazokinolin(amin) koji je odabran iz slijedeće formule (I): [image] pri čemu n
imiquimod, having the specific formula 1-isobutyl-1 H -imidazo[4,5- c]quinolin-4-amine, selected from following formula (X): and 
imikimod, koji ima specifičnu formulu 1-izobutil-1H-imidazo[4,5-c]kinolin-4-amin, koji je odabran iz slijedeće formule (X): [image] .
Pharmaceutical composition for use according to claim 1, the pharmaceutical composition further comprising at least one thermo-sensitive agent, wherein the at least one thermo-sensitive agent is selected from chitosan, or from a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymer (also termed PEO-PPO-PEO or poloxamer). 
Farmaceutski pripravak za upotrebu prema zahtjevu 1, naznačen time da farmaceutski pripravak nadalje sadrži barem jedno termoosjetljivo sredstvo, pri čemu barem jedno termoosjetljivo sredstvo je odabrano od kitosana, ili od kopolimera poli(etilen oksida)-poli(propilen oksida)-poli(etilen oksida) (također se naziva PEO-PPO-PEO ili poloksamer).
Pharmaceutical composition for use according to any of claims 1 or 2, the pharmaceutical composition comprising acetic and/or lactic acid in a concentration of 0.025 M to 0.200 M, preferably in a concentration of 0.025 M to 0.100 M or in a concentration of 0.100 M to 0.200 M or in a concentration of 0.075 to 0.125 M. 
Farmaceutski pripravak za upotrebu prema bilo kojem zahtjevu od 1 do 2, naznačen time da farmaceutski pripravak sadrži mliječnu kiselinu u koncentraciji od 0.025 M do 0.200 M, poželjno u koncentraciji od 0.025 M do 0.100 M ili u koncentraciji od 0.100 M do 0.200 M ili u koncentraciji od 0.075 do 1.125 M.
A composition for transdermal delivery comprising a drug-containing layer that comprises Gestodene or an ester thereof and a carrier selected from the group consisting of polyisobutylenes, polybutenes, polyisoprenes, polystyrenes, styrene isoprene styrene block polymers, styrene butadiene styrene block polymers and mixtures thereof, wherein the drug-containing layer has a solubility for said Gestodene of no more than 3% by weight of the drug-containing layer, and wherein the Gestodene or an ester thereof is present in an amount ranging between 0.5 and 3% by weight of the drug-containing layer. 
Komplet koji sadrži 1 do 11 jediničnih doza namijenjen za razdoblje liječenja od 12 tjedana koji je formuliran u obliku za transdermalno davanje Gestodena, te navedena jedinica doziranja sadrži pripravak za transdermalno davanje koji sadrži sloj koji sadrži lijek koji uključuje Gestoden i nosač koji je odabran iz skupine koja sadrži poliizobutilene, polibutene, poliizoprene, polistirene, stiren izopren stiren blok polimere, stiren butadien stiren blok polimere i njihove smjese, naznačen time da sloj koji sadrži lijek ima topljivost za navedeni Gestoden od ne više od 3% težinski sloja koji sadrži lijek, te pri čemu je Gestoden prisutan u količini u rasponu između 0.5 i 3% težinski sloja koji sadrži lijek.
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, dok inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol, te pritom prva količina i druga količina zajedno sastavljaju učinkovitu količinu za prevenciju ili liječenje upalne plućne bolesti.
Pharmaceutical composition according to claim 27, wherein the PDE4 inhibitor is ROFLUMILAST. 
Farmaceutski sastav prema zahtjevu 27, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
Pharmaceutical composition according to claim 27, wherein the PDE4 inhibitor is ROFLUMILASTN-oxide. 
Farmaceutski sastav prema zahtjevu 27, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.